Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1984 May;49(5):615–620. doi: 10.1038/bjc.1984.96

Recombinant interferon in advanced breast cancer.

A Nethersell, H Smedley, M Katrak, T Wheeler, K Sikora
PMCID: PMC1976731  PMID: 6722009

Abstract

Fifteen patients with locally advanced refractory breast cancer have been treated with recombinant leucocyte interferon ( rIFN -alpha A) for up to 12 weeks. Toxicity was considerable with the initial dosage schedule employed but became acceptable after reducing the starting dose by 50%. Minor side effects occurred in all patients and major CNS toxicity in six. Nine patients showed some evidence of tumour regression at 4 weeks. Only two of these were still responding at 12 weeks. Response was unrelated to the length of previous history, oestrogen receptor status or previous responsiveness to cytotoxic or hormone therapy.

Full text

PDF
615

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cantell K., Hirvonen S., Koistinen V. Partial purification of human leukocyte interferon on a large scale. Methods Enzymol. 1981;78(Pt A):499–505. doi: 10.1016/0076-6879(81)78161-8. [DOI] [PubMed] [Google Scholar]
  2. GRESSER I. Production of interferon by suspensions of human leucocytes. Proc Soc Exp Biol Med. 1961 Dec;108:799–803. doi: 10.3181/00379727-108-27072. [DOI] [PubMed] [Google Scholar]
  3. Giard D. J., Loeb D. H., Thilly W. G., Wang D. I., Levine D. W. Human interferon production with diploid fibroblast cells grown on microcarriers. Biotechnol Bioeng. 1979 Mar;21(3):433–442. doi: 10.1002/bit.260210306. [DOI] [PubMed] [Google Scholar]
  4. Goeddel D. V., Yelverton E., Ullrich A., Heyneker H. L., Miozzari G., Holmes W., Seeburg P. H., Dull T., May L., Stebbing N. Human leukocyte interferon produced by E. coli is biologically active. Nature. 1980 Oct 2;287(5781):411–416. doi: 10.1038/287411a0. [DOI] [PubMed] [Google Scholar]
  5. Horowitz B. Human interferon--properties, clinical application, and production. J Parenter Sci Technol. 1981 Sep-Oct;35(5):223–226. [PubMed] [Google Scholar]
  6. Smedley H., Katrak M., Sikora K., Wheeler T. Neurological effects of recombinant human interferon. Br Med J (Clin Res Ed) 1983 Jan 22;286(6361):262–264. doi: 10.1136/bmj.286.6361.262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Strander H., Mogensen K. E., Cantell K. Production of human lymphoblastoid interferon. J Clin Microbiol. 1975 Jan;1(1):116–117. doi: 10.1128/jcm.1.1.116-117.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES